{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T04:05:27Z","timestamp":1774497927809,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2015,3,13]],"date-time":"2015-03-13T00:00:00Z","timestamp":1426204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,3,13]],"date-time":"2015-03-13T00:00:00Z","timestamp":1426204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1038\/leu.2015.71","type":"journal-article","created":{"date-parts":[[2015,3,13]],"date-time":"2015-03-13T07:33:25Z","timestamp":1426232005000},"page":"1514-1523","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients"],"prefix":"10.1038","volume":"29","author":[{"given":"C M","family":"Lucas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R J","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A K","family":"Holcroft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L J","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Carmell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Polydoros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R E","family":"Clark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,13]]},"reference":[{"key":"BFleu201571_CR1","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1126\/science.3460176","volume":"233","author":"Y Ben-Neriah","year":"1986","unstructured":"Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D . The chronic myelogenous leukemia-specific p210 protein is the product of the BCR\/ABL hybrid gene. Science 1986; 233: 212\u2013214.","journal-title":"Science"},{"key":"BFleu201571_CR2","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1038\/leu.2008.225","volume":"22","author":"CM Lucas","year":"2008","unstructured":"Lucas CM, Wang L, Austin GM, Knight K, Watmough SJ, Shwe KH et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 2008; 22: 1963\u20131966.","journal-title":"Leukemia"},{"key":"BFleu201571_CR3","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","volume":"26","author":"H de Lavallade","year":"2008","unstructured":"de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26: 3358\u20133363.","journal-title":"J Clin Oncol"},{"key":"BFleu201571_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","volume":"8","author":"P Neviani","year":"2005","unstructured":"Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein. Cancer Cell 2005; 8: 355\u2013368.","journal-title":"Cancer Cell"},{"key":"BFleu201571_CR5","doi-asserted-by":"publisher","first-page":"6660","DOI":"10.1182\/blood-2010-08-304477","volume":"117","author":"CM Lucas","year":"2011","unstructured":"Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR, Clark RE . Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukaemia is a critical determinant of disease progression. Blood 2011; 117: 6660\u20136668.","journal-title":"Blood"},{"key":"BFleu201571_CR6","doi-asserted-by":"publisher","first-page":"5092","DOI":"10.1158\/1078-0432.CCR-08-3283","volume":"15","author":"C C\u00f4me","year":"2009","unstructured":"C\u00f4me C, Laine A, Chanrion M, Edgren 4H, Mattila E, Liu X et al. CIP2A Is associated with human breast cancer aggressivity. Clin Cancer Res 2009; 15: 5092\u20135100.","journal-title":"Clin Cancer Res"},{"key":"BFleu201571_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cell.2007.04.044","volume":"130","author":"MR Junttila","year":"2007","unstructured":"Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T et al. CIP2A inhibits PP2A in human malignancies. Cell 2007; 130: 51\u201362.","journal-title":"Cell"},{"key":"BFleu201571_CR8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1158\/2159-8290.CD-12-0292","volume":"3","author":"A Laine","year":"2013","unstructured":"Laine A, Sihto H, Come C, Rosenfeldt MT, Zwolinska A, Niemela M et al. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discov 2013; 3: 182\u2013197.","journal-title":"Cancer Discov"},{"key":"BFleu201571_CR9","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/jnci\/djp103","volume":"101","author":"A Khanna","year":"2009","unstructured":"Khanna A, Bockelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M et al. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Nati Cancer Inst 2009; 101: 793\u2013805.","journal-title":"J Nati Cancer Inst"},{"key":"BFleu201571_CR10","doi-asserted-by":"publisher","first-page":"e20159","DOI":"10.1371\/journal.pone.0020159","volume":"6","author":"L Ma","year":"2011","unstructured":"Ma L, Wen Z, Liu Z, Hu Z, Ma J, Chen X-Q et al. Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer. PLoS One 2011; 6: e20159.","journal-title":"PLoS One"},{"key":"BFleu201571_CR11","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/onc.2011.230","volume":"31","author":"DP Mathiasen","year":"2012","unstructured":"Mathiasen DP, Egebjerg C, Andersen SH, Rafn B, Puustinen P, Khanna A et al. Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation. Oncogene 2012; 31: 390\u2013401.","journal-title":"Oncogene"},{"key":"BFleu201571_CR12","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1751-553X.2010.01288.x","volume":"33","author":"J Wang","year":"2011","unstructured":"Wang J, Li W, Li L, Yu X, Jia J, Chen C . CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. Int J Lab Hematol 2011; 33: 290\u2013298.","journal-title":"Int J Lab Hematol"},{"key":"BFleu201571_CR13","first-page":"013","volume":"30","author":"G Yu","year":"2013","unstructured":"Yu G, Liu G, Dong J, Jin Y . Clinical implications of CIP2A protein expression in breast cancer. Med Oncol 2013; 30: 013\u20130524.","journal-title":"Med Oncol"},{"key":"BFleu201571_CR14","doi-asserted-by":"publisher","first-page":"R68","DOI":"10.1186\/bcr3175","volume":"14","author":"LM Tseng","year":"2012","unstructured":"Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, Chen KF . CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Res 2012; 14: R68.","journal-title":"Breast Cancer Res"},{"key":"BFleu201571_CR15","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1038\/onc.2011.599","volume":"31","author":"M Niemela","year":"2012","unstructured":"Niemela M, Kauko O, Sihto H, Mpindi J, Nicorici D, Pernila P et al. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes. Oncogene 2012; 31: 4266\u20134278.","journal-title":"Oncogene"},{"key":"BFleu201571_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/cam4.15","volume":"1","author":"LP Huang","year":"2012","unstructured":"Huang LP, Savoly D, Sidi AA, Adelson ME, Mordechai E, Trama JP . CIP2A protein expression in high-grade, high-stage bladder cancer. Cancer Med 2012; 1: 76\u201381.","journal-title":"Cancer Med"},{"key":"BFleu201571_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4161\/trns.22518","volume":"3","author":"R Pallai","year":"2012","unstructured":"Pallai R, Bhaskar A, Sodi V, Rice LM . Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells. Transcription 2012; 3: 6.","journal-title":"Transcription"},{"key":"BFleu201571_CR18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3233\/CBM-2011-0220","volume":"8","author":"LP Huang","year":"2010","unstructured":"Huang LP, Adelson ME, Mordechai E, Trama JP . CIP2A expression is elevated in cervical cancer. Cancer Biomark 2010; 8: 309\u2013317.","journal-title":"Cancer Biomark"},{"key":"BFleu201571_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/PDM.0b013e318249fd8b","volume":"21","author":"H He","year":"2012","unstructured":"He H, Wu G, Li W, Cao Y, Liu Y . CIP2A is highly expressed in hepatocellular carcinoma and predicts poor prognosis. Diagn Mol Pathol 2012; 21: 143\u2013149.","journal-title":"Diagn Mol Pathol"},{"key":"BFleu201571_CR20","first-page":"6","volume":"6","author":"WW Sung","year":"2013","unstructured":"Sung WW, Wang YC, Lin PL, Cheng YW, Chen CY, Wu TC et al. IL-10 promotes tumor aggressiveness via upregulation of CIP2A transcription in lung adenocarcinoma. Clin Cancer Res 2013; 6: 6.","journal-title":"Clin Cancer Res"},{"key":"BFleu201571_CR21","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1245\/s10434-010-1313-8","volume":"18","author":"Q-Z Dong","year":"2011","unstructured":"Dong Q-Z, Wang Y, Dong X-J, Li Z-X, Tang Z-P, Cui Q-Z et al. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol 2011; 18: 857\u2013865.","journal-title":"Ann Surg Oncol"},{"key":"BFleu201571_CR22","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1096\/fj.08-120550","volume":"23","author":"A Mukhopadhyay","year":"2009","unstructured":"Mukhopadhyay A, Saddoughi SA, Song P, Sultan I, Ponnusamy S, Senkal CE et al. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB j 2009; 23: 751\u2013763.","journal-title":"FASEB j"},{"key":"BFleu201571_CR23","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/0092-8674(92)90241-4","volume":"70","author":"CL Sawyers","year":"1992","unstructured":"Sawyers CL, Callahan W, Witte ON . Dominant negative MYC blocks transformation by ABL oncogenes. Cell 1992; 70: 901\u2013910.","journal-title":"Cell"},{"key":"BFleu201571_CR24","doi-asserted-by":"publisher","first-page":"364","DOI":"10.2298\/VSP0604364S","volume":"63","author":"M Strnad","year":"2006","unstructured":"Strnad M, Brajuskovi\u0107 G, Streli\u0107 N, Zivanovi\u0107 BT, Tuki\u0107 L, Stamatovi\u0107 D . Expression of Bcl-2 protein and the amplification of c-myc gene in patients with chronic myeloid leukemia. Vojnosanit Pregl 2006; 63: 364\u2013369.","journal-title":"Vojnosanit Pregl"},{"key":"BFleu201571_CR25","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.4161\/cc.6.9.4161","volume":"6","author":"EV Prochownik","year":"2007","unstructured":"Prochownik EV, Li Y . The ever expanding role for c-Myc in promoting genomic instability. Cell Cycle 2007; 6: 1024\u20131029.","journal-title":"Cell Cycle"},{"key":"BFleu201571_CR26","first-page":"68","volume":"31","author":"R Oudat","year":"2001","unstructured":"Oudat R, Khan Z, Glassman AB . Detection of trisomy 8 in philadelphia chromosome-positive CML patients using conventional cytogenetic and interphase fluorescence in situ hybridization techniques and its relation to c-myc involvement. Ann Clin Lab Sci 2001; 31: 68\u201374.","journal-title":"Ann Clin Lab Sci"},{"key":"BFleu201571_CR27","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1182\/blood-2006-12-065599","volume":"110","author":"M Mohty","year":"2007","unstructured":"Mohty M, Yong ASM, Szydlo RM, Apperley JF, Melo JV . The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood 2007; 110: 380\u2013383.","journal-title":"Blood"},{"key":"BFleu201571_CR28","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/0008-5472.CAN-11-2575","volume":"72","author":"D Engelmann","year":"2012","unstructured":"Engelmann D, P\u00fctzer BM . The dark side of E2F1: in transit beyond apoptosis. Cancer Res 2012; 72: 571\u2013575.","journal-title":"Cancer Res"},{"key":"BFleu201571_CR29","first-page":"1499","volume":"9","author":"MJ Stewart","year":"1995","unstructured":"Stewart MJ, Litz-Jackson S, Burgess GS, Williamson EA, Leibowitz DS, Boswell HS . Role for E2F1 in p210 BCR-ABL downstream regulation of c-myc transcription initiation. Studies in murine myeloid cells. Leukemia 1995; 9: 1499\u20131507.","journal-title":"Leukemia"},{"key":"BFleu201571_CR30","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1002\/j.1460-2075.1994.tb06635.x","volume":"13","author":"P Singh","year":"1994","unstructured":"Singh P, Wong SH, Hong W . Overexpression of E2F-1 in rat embryo fibroblasts leads to neoplastic transformation. EMBO J 1994; 13: 3329\u20133338.","journal-title":"EMBO J"},{"key":"BFleu201571_CR31","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/nature07066","volume":"454","author":"S-Y Tsai","year":"2008","unstructured":"Tsai S-Y, Opavsky R, Sharma N, Wu L, Naidu S, Nolan E et al. Mouse development with a single E2F activator. Nature 2008; 454: 1137\u20131141.","journal-title":"Nature"},{"key":"BFleu201571_CR32","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1096\/fj.02-0431rev","volume":"17","author":"SD Mundle","year":"2003","unstructured":"Mundle SD, Saberwal G . Evolving intricacies and implications of E2F1 regulation. FASEB J 2003; 17: 569\u2013574.","journal-title":"FASEB J"},{"key":"BFleu201571_CR33","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/nrc2718","volume":"9","author":"S Polager","year":"2009","unstructured":"Polager S, Ginsberg D . p53 and E2f: partners in life and death. Nat Rev Cancer 2009; 9: 738\u2013748.","journal-title":"Nat Rev Cancer"},{"key":"BFleu201571_CR34","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/leu.2012.134","volume":"26","author":"RA Larson","year":"2012","unstructured":"Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012; 26: 2197\u20132203.","journal-title":"Leukemia"},{"key":"BFleu201571_CR35","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","volume":"119","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012; 119: 1123\u20131129.","journal-title":"Blood"},{"key":"BFleu201571_CR36","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1365-2141.2009.08066.x","volume":"149","author":"CM Lucas","year":"2010","unstructured":"Lucas CM, Harris RJ, Giannoudis A, Knight K, Watmough SJ, Clark RE . BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL\/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia. Br J Haematol 2010; 149: 458\u2013460.","journal-title":"Br J Haematol"},{"key":"BFleu201571_CR37","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1046\/j.1365-2141.2003.04200.x","volume":"120","author":"L Wang","year":"2003","unstructured":"Wang L, Pearson K, Ferguson JE, Clark RE . The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol 2003; 120: 990\u2013999.","journal-title":"Br J Haematol"},{"key":"BFleu201571_CR38","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","volume":"30","author":"D Marin","year":"2012","unstructured":"Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012; 30: 232\u2013238.","journal-title":"J Clin Oncol"},{"key":"BFleu201571_CR39","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1182\/blood-2012-11-466037","volume":"121","author":"P Neelakantan","year":"2013","unstructured":"Neelakantan P, Gerrard G, Lucas C, Milojkovic D, May P, Wang L et al. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood 2013; 121: 2739\u20132742.","journal-title":"Blood"},{"key":"BFleu201571_CR40","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/sj.leu.2404189","volume":"20","author":"A Hamilton","year":"2006","unstructured":"Hamilton A, Elrick L, Myssina S, Copland M, Jorgensen H, Melo JV et al. BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry. Leukemia 2006; 20: 1035\u20131039.","journal-title":"Leukemia"},{"key":"BFleu201571_CR41","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1182\/blood-2005-03-1103","volume":"106","author":"DL White","year":"2005","unstructured":"White DL, Saunders V, Lyons AB, Branford S, Grigg A, To LB et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 2005; 106: 2520\u20132526.","journal-title":"Blood"},{"key":"BFleu201571_CR42","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","volume":"103","author":"B Calabretta","year":"2004","unstructured":"Calabretta B, Perrotti D . The biology of CML blast crisis. Blood 2004; 103: 4010\u20134022.","journal-title":"Blood"},{"key":"BFleu201571_CR43","doi-asserted-by":"publisher","first-page":"6293","DOI":"10.1073\/pnas.88.14.6293","volume":"88","author":"E Feinstein","year":"1991","unstructured":"Feinstein E, Cimino G, Gale RP, Alimena G, Berthier R, Kishi K et al. p53 in chronic myelogenous leukemia in acute phase. Proc Natl Acad Sci USA 1991; 88: 6293\u20136297.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu201571_CR44","doi-asserted-by":"publisher","first-page":"6783","DOI":"10.1073\/pnas.86.17.6783","volume":"86","author":"H Ahuja","year":"1989","unstructured":"Ahuja H, Bar-Eli M, Advani SH, Benchimol S, Cline MJ . Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. PNAS 1989; 86: 6783\u20136787.","journal-title":"PNAS"},{"key":"BFleu201571_CR45","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1172\/JCI31095","volume":"117","author":"P Neviani","year":"2007","unstructured":"Neviani P, Santhanam R, Oaks J, Eiring A, Notari M, Blaser B et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 2007; 117: 2408\u20132421.","journal-title":"J Clin Invest"},{"key":"BFleu201571_CR46","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/emmm.201201283","volume":"5","author":"SA Saddoughi","year":"2013","unstructured":"Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J et al. Sphingosine analogue drug FTY720 targets I2PP2A\/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med 2013; 5: 105\u2013121.","journal-title":"EMBO Mol Med"},{"key":"BFleu201571_CR47","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1172\/JCI68951","volume":"123","author":"P Neviani","year":"2013","unstructured":"Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest 2013; 123: 4144\u20134157.","journal-title":"J Clin Invest"},{"key":"BFleu201571_CR48","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.diff.2010.04.003","volume":"80","author":"L Kerosuo","year":"2010","unstructured":"Kerosuo L, Fox H, Per\u00e4l\u00e4 N, Ahlqvist K, Suomalainen A, Westermarck J et al. CIP2A increases self-renewal and is linked to Myc in neural progenitor cells. Differentiation 2010; 80: 68\u201377.","journal-title":"Differentiation"},{"key":"BFleu201571_CR49","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/path.2178","volume":"212","author":"HM Amin","year":"2007","unstructured":"Amin HM, Hoshino K, Yang H, Lin Q, Lai R, Garcia-Manero G . Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (Shp1) is associated with progression of chronic myeloid leukaemia. J Pathol 2007; 212: 402\u2013410.","journal-title":"J Pathol"},{"key":"BFleu201571_CR50","doi-asserted-by":"publisher","first-page":"8905","DOI":"10.1074\/jbc.272.14.8905","volume":"272","author":"MC Birchenall-Roberts","year":"1997","unstructured":"Birchenall-Roberts MC, Yoo YD, Bertolette DC 3rd, Lee KH, Turley JM, Bang OS et al. The p120-v-Abl protein interacts with E2F-1 and regulates E2F-1 transcriptional activity. J Biol Chem 1997; 272: 8905\u20138911.","journal-title":"J Biol Chem"},{"key":"BFleu201571_CR51","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1182\/blood-2007-05-090472","volume":"111","author":"AM Eiring","year":"2008","unstructured":"Eiring AM, Neviani P, Santhanam R, Oaks JJ, Chang JS, Notari M et al. Identification of novel posttranscriptional targets of the BCR\/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR\/ABL leukemogenesis. Blood 2008; 111: 816\u2013828.","journal-title":"Blood"},{"key":"BFleu201571_CR52","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1371\/journal.pbio.0030401","volume":"3","author":"G Bilousova","year":"2005","unstructured":"Bilousova G, Marusyk A, Porter CC, Cardiff RD, DeGregori J . Impaired DNA replication within progenitor cell pools promotes leukemogenesis. PLoS Biol 2005; 3: e401.","journal-title":"PLoS Biol"},{"key":"BFleu201571_CR53","doi-asserted-by":"crossref","unstructured":"Lucas CM, Harris RJ, Giannoudis A, Clark RE . c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia. Haematologica 2015; e-pub ahead of print 6 February 2015.","DOI":"10.3324\/haematol.2014.115691"},{"key":"BFleu201571_CR54","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1074\/jbc.M113.507954","volume":"289","author":"AL Jeong","year":"2014","unstructured":"Jeong AL, Lee S, Park JS, Han S, Jang C-Y, Lim J-S et al. Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) Protein Is Involved in Centrosome Separation through the Regulation of NIMA (Never In Mitosis Gene A)-related Kinase 2 (NEK2) Protein Activity. J Biol Chem 2014; 289: 28\u201340.","journal-title":"J Biol Chem"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201571.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201571","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201571.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:20:39Z","timestamp":1648743639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,13]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["BFleu201571"],"URL":"https:\/\/doi.org\/10.1038\/leu.2015.71","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,13]]},"assertion":[{"value":"28 August 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"REC has received research funding from Novartis, Bristol Myers Squibb, Pfizer Sanofi (not related to this publication), and is a member of the speakers bureau for Novartis and (not related to this publication) Sanofi. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}